

CHIMERIC THERAPEUTICS APPOINTS DR NADER SANAI & DR LARRY COUTURE TO SCIENTIFIC ADVISORY BOARD

HIGHLIGHTS

- Dr Nader Sanai – internationally recognized tumor surgeon with practice devoted entirely to patients with benign and malignant brain tumors. Director of the Ivy Brain Tumor Center, overseeing all brain tumor research at the Barrow Neurological Institute.
 - Dr Larry Couture – specialising in cellular and genetic therapies as well as first-in-human trials. Currently Founding Director/Senior Vice President of City of Hope’s Center for Applied Technology.
 - Chimeric Therapeutics is focused on development of CLTX CAR-T, which uses a peptide derived from scorpion toxin to direct T cells to target glioblastoma.
 - Phase 1 trial underway at City of Hope cancer centre in Los Angeles, where the technology was developed by CAR-T specialist Professor Christine Brown.
-

Chimeric Therapeutics (Chimeric or the Company), a drug development company focused on novel CAR-T cell therapies for solid tumors, is pleased to announce the appointment of Dr Nader Sanai and Dr Larry Couture to its Scientific Advisory Board.

Dr Nader Sanai

Dr Sanai is the J.N. Harber Professor of Neurological Surgery and also holds the Francis & Dionne Najafi Chair in Neurosurgical Oncology. As an internationally-recognised brain tumor surgeon, his specialty clinical practice is devoted entirely to patients with benign and malignant brain tumors, particularly those in high-risk areas. He is a world-expert in using brain mapping techniques to identify and preserve areas of motor, sensory, and language function during surgery. As one of the nation’s highest-volume neurosurgical oncologists, Dr Sanai was elected, in 2016, as the youngest member of the American Academy of Neurological Surgeons, the most respected academic organisation in neurosurgery.

As Director of the Ivy Brain Tumor Center, Dr Sanai oversees all brain tumor research at the Barrow Neurological Institute. The Ivy Center includes over 50 scientists, clinicians, and clinical trial specialists and is a world leader in designing experimental treatments for brain cancer. Its precision medicine drug development program pioneered the use of Phase 0 clinical trials to accelerated new drug discovery for incurable brain tumors.

Dr Sanai’s brain tumor research efforts are funded by over a dozen external granting agencies, including the National Institutes of Health (NIH) and the Ben & Catherine Ivy Foundation. Dr Sanai is one of only a handful of neurosurgeons in the US serving as the principal investigator for multiple NIH R01 grants. Collectively, Dr Sanai’s published research has led to over 15,000 total citations and an *h* index of 47 – one of the highest for an academic neurosurgeon in the United States, where the median for a Department Chair is 22.

Dr Larry Couture

Dr Couture has over 30 years’ experience in cellular and genetic therapies. He has been a key participant in

numerous first-in-man clinical studies, including the first human gene therapy trials, first administration to humans of a genetically engineered virus and many other cell and gene therapy milestones.

He was the Founding Director/Senior Vice President of City of Hope's Center for Applied Technology and Founding Director of its Center for Biomedicine and Genetics. He served for six years on the FDA's Cellular, Tissue and Gene Therapy Advisory Committee. His industry experience includes Genzyme Corp and Ribozyme Pharmaceuticals, Inc.

His current executive roles include, CEO Orbsen Therapeutics, CEO Arrogene Inc, Ltd, President/Co-Chairman of Vault Nano Inc, COO Westwood Bioscience Inc, President/CSO LongLifeRx Inc, CSO Fortem Neuroscience Inc, COO/CSO Novonco Inc, and Managing Partner of The Multiverse Fund I.

Chimeric's Executive Chairman Paul Hopper commented on the new appointments:

"We've identified some of the most well-regarded specialists in neurology and CAR-T technology to form our Scientific Advisory Board and assist in the development of our CLTX CAR-T asset.

"The knowledge and experience of Dr Sanai and Dr Couture add significant strength to this, and we expect to make important additional appointments in the near future."

Chimeric is currently developing the ground-breaking CLTX CAR-T therapy for solid tumors, based on scientific research conducted at the City of Hope (COH) Cancer Centre in Los Angeles. CLTX-CAR incorporates chlorotoxin, a peptide derived from scorpion toxin, as a novel CAR tumor recognition domain which directs T cells to target glioblastoma.

The first patient in an IND-approved Phase 1 glioblastoma trial of CLTX CAR-T, being conducted at COH, was dosed earlier this month.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics is developing ground-breaking CAR-T cell therapies for solid tumors based on scientific research conducted by leading US CAR-T experts at the City of Hope (COH) Cancer Centre in Los Angeles. Its CLTX-CAR T technology incorporates chlorotoxin (CLTX), a peptide derived from scorpion toxin, as a novel CAR tumor recognition domain. This domain extends the range of CAR-T cell targeting in solid tumors.

Potent antitumor activity against glioblastoma (GBM) has been established in preclinical models. Currently undergoing Phase 1 clinical trials in GBM at COH, CLTX CAR-T has significant drug administration benefits since it can be delivered during an outpatient visit.

CLTX CAR-T cells differ from other GBM-targeting immunotherapies by its specific and broad recognition of patient tumors and of the majority of cells within these tumors. CLTX CAR-T cells target GBM through recognition of a receptor complex composed of membrane-bound matrix metalloprotease 2 (MMP2) and involving the chloride channel CLC3.

CLTX CAR-T cells do not exhibit off-tumor recognition of normal human or murine cells/tissues in preclinical models, consistent with the documented safety of administering other CLTX-containing therapeutic agents in humans.

The CLTX peptide has also demonstrated safety and specificity in clinical testing as a radiotherapy delivery conjugate and as an imaging agent in fluorescence-guided surgery for recurrent/refractory GBM.

CONTACT

Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com
W: www.chimerictherapeutics.com